Adrenal Cortex Carcinoma

P=N/A, N=54, Recruiting, The Cleveland Clinic | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Aug 2026

P=N/A, N=62, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

P=N/A, N=180, Not yet recruiting, Shanxi Bethune Hospital; Shanxi Bethune Hospital

Our findings highlight CDK1 as a prognostic marker and a therapeutic target across multiple cancers, with particular relevance in ACC. By integrating pan-cancer transcriptomic analysis with structure-based drug discovery, this study not only emphasizes the clinical significance of CDK1 in ACC but also proposes natural compound-derived inhibitors as promising candidates for future therapeutic development.

ANLN may be a prognostic biomarker for patients with ACC and may play a role in tumor biology. Further studies are needed to determine whether ANLN is clinically useful as a prognostic factor in the treatment of ACC and to clarify its involvement in the mechanism of malignant progression of ACC.

This case highlights the complexity of interpreting mosaic variants in the TP53 gene, and we propose a testing algorithm to aid in the delineation of this phenomenon when relaying cancer and reproductive risk information in the context of mosaicism.

P2, N=157, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028

Molecular imaging can make an essential contribution to the noninvasive diagnosis of adrenal tumors, pheochromocytomas, and paragangliomas by visualizing various metabolic processes.

In summary, DR3 is a multifunctional molecule with significant potential as a biomarker and therapeutic target. However, its duality and context-dependent effects necessitate the development of personalized strategies based on tumor molecular subtyping.

These findings identify the steroid phenotype as a critical regulator of immune escape in ACC. Our results support incorporating this stratification as a biomarker for patient selection, identifying LSP tumors as the subgroup most likely to benefit from immune checkpoint blockade due to their "hot" yet exhausted microenvironment.

The integration of multimodal diagnostic techniques, particularly AVS, is valuable for localizing hormonally active tumors. Preliminary mechanistic insights suggest a potential role for epigenetic dysregulation in the pathogenesis of this tumor type.

P2, N=30, Active, not recruiting, National Cancer Center, Korea | Enrolling by invitation --> Active, not recruiting | Trial completion date: Aug 2026 --> Feb 2027 | Trial primary completion date: Aug 2025 --> Feb 2027